onc brain

About · curated by Nick Boehling, MD · @nb2276

    2026-05-29 ASCO Annual Meeting 2026

    digest generated 2026-07-19

    Wait or Treat?: upfront cranial RT cut 2y intracranial PD (21.7% vs 50%, sub-HR 0.35) but no OS gain in asymptomatic EGFR/ALK NSCLC brain mets.
    TL;DR
    CNS carried the day. The first phase III on cranial-RT timing for asymptomatic BM in TKI-treated EGFR/ALK NSCLC shows upfront RT controls the brain (sub-HR 0.35) yet doesn't extend survival, which numerically favored deferral (HR 1.45). Argues for CNS-active-TKI-first: hold RT until intracranial PD.

    CNS

    The question is timing, not addition, of cranial RT when a CNS-active TKI is already holding the brain.

    Confirmatory

    Wait or Treat? NCT05236946

    ForAsymptomatic brain mets, EGFR/ALK-mutant metastatic NSCLC, on TKI + chemo

    Intracranial PFS local control

    Sub-HR 0.35

    95% CI 0.21-0.59, p<0.001; favors upfront RT

    TL;DRUpfront cranial RT cut 2y intracranial progression (21.7% vs 50%, sub-HR 0.35) but no OS gain; survival numerically favored delayed (HR 1.45).

    Why it mattersRadiation oncology

    The primary endpoint actually favored upfront RT (2y intracranial progression 21.7% vs 50%, sub-HR 0.35), yet OS trended toward delayed (2y 48% vs 60%) with 6% radiation necrosis vs none. Better CNS control bought no survival and added toxicity, so upfront cranial RT can be safely deferred to intracranial progression.

    Wait or Treat?
    EndpointUpfront RTDelayed RT
    Events2047
    1-yr intracranial PD8.7% (2.9-14.5)25.7% (16.8-34.7)
    2-yr intracranial PD21.7% (12.6-30.8)50% (39.2-60.9)
    Sub-HR (95% CI)0.35 (0.21-0.59), p<0.001ref
    8 details 4 trials watching
    Design

    Phase 3 open-label RCT, 1:1, N=208 (105 upfront cranial RT vs 103 delayed) at a single center (Tata Memorial). Median follow-up 30.6 mo; stratified by GPA and synchronous vs metachronous BM.

    Population & inclusion

    Metastatic EGFR- or ALK-mutant NSCLC with radiologically measurable, completely asymptomatic brain metastases, ECOG 0-2. Both arms received TKI + chemotherapy.

    Radiotherapy

    Delayed arm held cranial RT until intracranial progression or patient request, with MRI brain q3mo for year 1 then q6mo. RT dose, fractionation, and technique (SRS vs WBRT) not reported in source.

    Endpoints

    Primary: intracranial PFS. Secondary: OS, PFS, toxicity, ORR, neurocognition, PROM.

    Results

    Primary endpoint met for intracranial control but did not translate to survival; the OS trend and radiation-necrosis signal both favored deferral. See the intracranial-progression figure and survival table for effect sizes.

    vs leading data

    First randomized evidence on RT timing in this population. Consistent with the CNS-active TKI era (osimertinib, alectinib, lorlatinib), where strong systemic intracranial control supports deferring RT.

    Applies to
    asymptomatic brain metastases in EGFR/ALK-mutant metastatic NSCLC on TKI plus chemotherapy
    Does not represent symptomatic brain mets, oncogene-negative NSCLC, or pts needing immediate neurologic intervention.
    Limitations

    Open-label and single-institution. Powered for intracranial PFS, not OS, so the survival and necrosis signals favoring deferral are secondary. RT technique not reported.

    Rationale

    Randomized phase 3, primary intracranial-PFS endpoint met, but no OS benefit and less necrosis with deferral; backs the emerging TKI-first, defer-RT approach in oncogene-driven NSCLC.

    Monday clinic

    In asymptomatic brain metastases from EGFR/ALK-mutant metastatic NSCLC on TKI plus chemo, this supports deferring cranial RT until intracranial progression; it does not extend to symptomatic brain mets or oncogene-negative NSCLC.

    Open questions

    Sourced from @OncLive, @DrRiyazShah, @StephenVLiu

    📚 Sources · 🐦 3 tweets

    Radiation Palliative Phase 3 RCT Confirmatory ASCO Annual Meeting 2026